• Browse
• Meine Registrierung (Login)
• Registrierung (frei)

Pharmaceutical News

• Glivec Receives US Approval As First Treatment To Reduce Risk Of Cancer Returning In Pat ...
  Sat, 27 December 2008
  Novartis announced that Glivec (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Glivec is now the only post-surgery treatment indicated to dela ...
• Merck Serono Acquires Manufacturing Rights And Facility For Stimuvax From Oncothyreon
  Fri, 26 December 2008
  Merck Serono, a division of Merck KGaA, announced recently that it has modified the license from Oncothyreon to include the right to manufacture Stimuvax (BLP25 liposome vaccine) and also has purchased current inventory and certain assets used for the manufacture of Stimuvax from Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) for ...
• BioCryst Pharmaceuticals Continues Forodesine HCl Program In Chronic Lymphocytic Leukemia
  Fri, 26 December 2008
  BioCryst Pharmaceuticals (Nasdaq: BCRX) announced interim data from the ongoing Forodesine HCl Phase 2 program in patients with chronic lymphocytic leukemia (CLL) and data from a healthy subject pharmacokinetic and pharmacodynamic study. The CLL study will continue with an amendment to study a new dosing regimen of oral For ...
• Arpida Publishes Top-Line Data Of Phase II Intravenous-To-Oral Switch Trial With Oral Ic ...
  Fri, 26 December 2008
  Arpida Ltd. (SWX: ARPN) announces positive top-line data of the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI). The top-line results demonstrated high clinical cure rates of over 90% following the step-down therapy with oral ic ...
• Gilda's Club Worldwide Spells 'HOPE' To Colon Cancer Patients And Survivors
  Fri, 26 December 2008
  Cancer advocacy organization Gilda's Club Worldwide offers a message of hope this holiday season to the millions touched by colon cancer with a one-of-a-kind mosaic mural at its New York City headquarters. The 15X6 foot mural was created by more than 165 colon cancer survivors from around the nation as part of a new MOSAIC o ...
• NeurogesX Announces FDA Acceptance To Review New Drug Application For NGX-4010 To Treat ...
  Fri, 26 December 2008
  NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) to review its investigational product candidate, NGX-4010, for the management of pain d ...
• Intercell Update On Technology Partnerships: Intercell Outlicenses Group B Streptococcus ...
  Fri, 26 December 2008
  Intercell announced that the Company has transferred on an exclusive basis its pre-clinical Group B Streptococcus (GBS) vaccine program to Novartis. At the same time Intercell has kept and received co-exclusive rights for the development of therapeutic antibodies against Group B Streptococcus and has in-licensed additional r ...
• Memory Pharmaceuticals Reports Phase 1 Data For R4996/MEM 63908
  Fri, 26 December 2008
  Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced positive results from its Phase 1 program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with Roche for cognitive disorders such as Alzheimer's disease. The Phase 1 program enrolled over 130 subjects and included ...
• NanoKTN And The Wellcome Trust Collaborate On Nano 4 Life Conference, UK
  Thu, 25 December 2008
  Converging Nanotechnology and the Life Science Industry Wednesday 11th February 2009, London The Nanotechnology Knowledge Transfer Network (NanoKTN), one of the UK's primary knowledge-based networks for Micro and Nanotechnologies, has announced that their first Nano 4 Life event will take place on Wednesday 11th February ...
• Among Older Adults, Prescription And Over-the-Counter Medications Are Commonly Used Together
  Thu, 25 December 2008
  A survey suggests that nearly half of older adults in the U.S. use prescription and over-the-counter medications together, and that about 4 percent of older adults are potentially at risk of an adverse drug reaction because of an interaction between medications, according to a study in the December 24/31 issue ofJAMA. The re ...